Bioactive Adrenomedullin, Organ Support Therapies, and Survival in the Critically Ill: Results from the French and European Outcome Registry in ICU Study

What Was Tested

Researchers studied Adrenomedullin in this observational study publication.

Adrenomedullin has vascular properties and elevated plasma adrenomedullin levels were detected in sepsis.

The researchers assessed, in septic and nonseptic ICU patients, the relation between circulating adrenomedullin, the need for organ support and mortality, using an assay of bioactive adrenomedullin.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Consecutive patients admitted to intensive care with a requirement for invasive mechanical ventilation and/or vasoactive drug support for more than 24 hours following ICU admission and discharged from ICU were included.

The main outcome was the need for organ support, including renal replacement therapy and/or for inotrope(s) and/or vasopressor(s).

How the Study Was Run

In design terms this was a multicenter study.

More than one site took part, so the participants came from several places.

Prospective multicenter observational cohort study.

Data from the French and euRopean Outcome reGistry in ICUs study.

Clinical and biological parameters were collected at baseline, including bioactive-adrenomedullin.

Status of ICU survivors was assess until 1 year after discharge.

Secondary endpoints were the ICU length of stay and the 28-day all-cause mortality.

What Was Measured

PubMed files the paper under topics including Adrenomedullin, Cohort Studies, Critical Illness, Europe, France, Intensive Care Units and Outcome Assessment, Health Care.

What This Means in Plain Language

The paper is a multicenter study of Adrenomedullin.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Critical care medicine), a journal based in United States.

More context: the Adrenomedullin compound page, all human trials.